Cargando…

Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention

BACKGROUND: Although it has been shown to be superior to simple antithrombotic drug therapy, most patients are unable to receive timely percutaneous coronary intervention (PCI) and are treated with conventional triple antithrombotic therapy (aspirin, clopidogrel, low-molecular-weight heparin). Here,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lan, Ge, Zhenrong, Zhang, Dengke, Kuang, Jun, Ma, Xiang, Jiang, Shubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701602/ https://www.ncbi.nlm.nih.gov/pubmed/29200825 http://dx.doi.org/10.2147/DDDT.S138714

Ejemplares similares

Immediate percutaneous coronary intervention in NSTE-ACS: the sun is not hurried by early risers
por: Knaapen, P.
Publicado: (2016)

Application of Layered Strain Technique in NSTE-ACS
por: Zhao, Nan, et al.
Publicado: (2022)

Indications for an early invasive strategy in NSTE-ACS patients
por: Zwart, B., et al.
Publicado: (2019)

Optimal treatment of patients with NSTE-ACS in the Dutch health care system
por: van Kuijk, J. P., et al.
Publicado: (2018)

Collateral damage of COVID-19-lockdown in Germany: decline of NSTE-ACS admissions
por: Gitt, A. K., et al.
Publicado: (2020)

An analysis of patients receiving emergency CAG without PCI and the value of GRACE score in predicting PCI possibilities in NSTE-ACS patients
por: Zhou, Bo-Da, et al.
Publicado: (2015)

Occurrence of Severe Arrhythmias in Patients with Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Retrospective Study
por: Wilmé, Valérie, et al.
Publicado: (2023)

Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement
por: Cohen, Marc
Publicado: (2009)

Single-Session Versus Staged Multivessel Optimal IVUS-Guided PCI in Patients With CCS or NSTE-ACS
por: Yamamoto, Ko, et al.
Publicado: (2023)

Association of neutrophil to lymphocyte ratio (NLR) with angiographic SYNTAX score in patients with non-ST-Segment elevation acute coronary syndrome (NSTE-ACS)
por: Maleki, Mehdi, et al.
Publicado: (2021)

Intracoronary administration of tirofiban during percutaneous coronary intervention facilitates patients with acute coronary syndrome
por: Jia, Helei, et al.
Publicado: (2017)

Tirofiban: A Rare Cause of Thrombocytopenia in a Patient Undergoing Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report
por: Wang, Ze-Mu, et al.
Publicado: (2023)

Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention
por: Kupó, Péter, et al.
Publicado: (2016)

Ex vivo signatures of myocardial edema by in vivo T2-CMR in a novel large animal model of NSTE-ACS
por: Chang, Henry, et al.
Publicado: (2013)

NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View
por: Angoulvant, Denis, et al.
Publicado: (2021)

Influence of Tirofiban maintenance duration on patients with acute myocardial infarction treated by percutaneous coronary intervention
por: Ji, Zhen-Guo, et al.
Publicado: (2015)

Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial
por: Gimbel, Marieke E., et al.
Publicado: (2020)

The Effect of the Timing of Invasive Management on Cardiac Function in Patients with NSTE-ACS, Insights from the OPTIMA-2 Randomized Controlled Trial
por: Fagel, Nick D., et al.
Publicado: (2021)

Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban
por: Campo, Gianluca, et al.
Publicado: (2010)

The effects of Anisodamine-Tirofiban Combined Therapy in acute myocardial infarction treated with Percutaneous Coronary Intervention (PCI)
por: Jiao, Yan, et al.
Publicado: (2022)

Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
por: Rola, Piotr, et al.
Publicado: (2022)

Comprehensive evaluation of time-varied outcomes for invasive and conservative strategies in patients with NSTE-ACS: a meta-analysis of randomized controlled trials
por: Zhao, Yi-Jing, et al.
Publicado: (2023)

Elevated TyG Index Predicts Incidence of Contrast-Induced Nephropathy: A Retrospective Cohort Study in NSTE-ACS Patients Implanted With DESs
por: Li, Mingkang, et al.
Publicado: (2022)

Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention
por: Wang, Haixia, et al.
Publicado: (2020)

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
por: Guo, Yong-zhe, et al.
Publicado: (2021)

Tirofiban-induced thrombocytopenia
por: Wang, Jun, et al.
Publicado: (2023)

Clinical and Angiographic Profile in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) and Chronic Stable Angina: A Tertiary Care Centre-Based Cohort Study From Southern Indian Population
por: Raju, Venkatesh
Publicado: (2023)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study
por: Kim, Yong-Won, et al.
Publicado: (2020)

Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial
por: Lee, Wonjae, et al.
Publicado: (2018)

Ability of FFR-CT to detect the absence of hemodynamically significant lesions in patients with high-risk NSTE-ACS admitted in the emergency department with chest pain, study design and rationale
por: Meier, David, et al.
Publicado: (2020)

Role of Copeptin and hs-cTnT to Discriminate AHF from Uncomplicated NSTE-ACS with Baseline Elevated hs-cTnT—A Derivation and External Validation Study
por: von Haehling, Stephan, et al.
Publicado: (2023)

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study
por: Lago, Igor Matos, et al.
Publicado: (2016)

Predictive value of the age, creatinine and ejection fraction score in patients undergoing primary percutaneous coronary intervention with bail-out tirofiban therapy
por: Ösken, Altuğ, et al.
Publicado: (2021)

Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials
por: Tang, Xiuying, et al.
Publicado: (2015)

A Simple Clinical Pre-procedure Risk Model for Predicting Thrombocytopenia Associated With Periprocedural Use of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention
por: Yi, Yi-Hu, et al.
Publicado: (2018)

The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function
por: Peng, Rui, et al.
Publicado: (2022)

Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry
por: Rigattieri, Stefano, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o5ku3adf694as87h17r5v7nurg